Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study

BACKGROUND: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events (N = 6784). HYPOTHESIS: Because previous real‐world studies have not reporte...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cardiol
Asıl Yazarlar: Camm, A. John, Amarenco, Pierre, Haas, Sylvia, Bach, Miriam, Kirchhof, Paulus, Kuhls, Silvia, Lambelet, Marc, Turpie, Alexander G.G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Wiley Periodicals, Inc. 2020
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724214/
https://ncbi.nlm.nih.gov/pubmed/32896928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23452
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller